KBC Group
PVLA icon

KBC Group’s Palvella Therapeutics PVLA Stock Holding History

KBC Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$31K Hold
224
– – ﹤0.01% 1804
2026
Q2 		$34K Hold
224
– – ﹤0.01% 1809
2026
Q1 		$28K Buy
+224
New +$23.4K ﹤0.01% 1811

Other funds holding PVLA

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return
Clio Asset Management
Clio Asset Management Charlottesville, Virginia $119M AUM 1.1% 1-Year Est. Return
Nan Fung Trinity
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Lisanti Capital Growth
Lisanti Capital Growth New York $373M AUM 178.76% 1-Year Est. Return

KBC Group's PVLA Position: Q3 2026 in Review

KBC Group held its Palvella Therapeutics (PVLA) position steady in Q3 2026 at 224 shares worth $31K. The position accounts for ﹤0.01% of the portfolio, ranked #1804.

KBC Group first reported a position in PVLA in Q1 2026 and has held it in 3 quarters since. The position peaked at $34K in Q2 2026. 71 funds tracked by Wall St. Rank hold PVLA as of Q3 2026.

  • KBC Group held 224 shares of Palvella Therapeutics worth $31K as of Q3 2026.
  • KBC Group left its Palvella Therapeutics share count unchanged in Q3 2026.
  • Palvella Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1804 holding.
  • KBC Group first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • KBC Group's Palvella Therapeutics position peaked at $34K in Q2 2026.
  • 71 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.